Back

The role of SGLT2 inhibitors in CV risk reduction in patients with type 2 diabetes

1 September 2019 (13:05 - 13:20)
Organised by:
Congress Presentation Part of: SGLT2 inhibitors in clinical cardiology: modern-day cardiovascular management in patients with type 2 diabetes Diabetes and the Heart ESC Premium Access ESC Congress 2019

About the speaker

Photo
Professor Sanjay Kaul

Cedars-Sinai Medical Centre, Los Angeles (United States of America)

4 More presentations in this session

Presentation thumbnail
Welcome and introduction
Professor T. Luescher (London, GB)
Slides Video
Presentation thumbnail
Taking the initiative: the cardiologist´s perspective
Professor N. Marx (Aachen, DE)
Slides Video
Presentation thumbnail
The SGLT2 inhibitor era: what more can we expect?
Professor S. Anker (Berlin, DE)
Slides Video
Presentation thumbnail
Audience questions and answers, summary and close
Professor T. Luescher (London, GB)
Video

Access the full session

Session thumbnail
SGLT2 inhibitors in clinical cardiology: modern-day cardiovascular management in patients with type 2 diabetes

The Event

Event poster

ESC Congress 2019

1 September 2019 13:05 CET
You may be interested in
thumbnail
Congress Presentation
Cardiovascular benefits of SGLT2i in type 2 diabetes without heart failure: a subgroup analysis
30 August 2025
thumbnail
Congress Presentation
SGLT2 inhibitors for obesity
31 August 2024
thumbnail
Congress Session
Risk prediction and treatment: bring your crystal ball?
19 May 2025
thumbnail
Congress Session
Innovative drug therapies in heart failure
18 May 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources